For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Genelabs Technologies, Inc.

USPTO Granted Patents = 72

% Expired Patents = 27.8

CIPO Patents = 1

Forward Citations = 1,190

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

Kirk E Fry (19 out of 39 patents)

Gregory R Reyes (18 out of 27 patents)

Christopher Don Roberts (17 out of 22 patents)

4. Jungsuh P Kim (12 out of 13 patents)

5. Cynthia A Edwards (12 out of 12 patents)

6. Charles Cantor (11 out of 101 patents)

7. Natalia Dyatkina (11 out of 23 patents)

8. Beth M Andrews (11 out of 11 patents)

9. Jesse Daniel Keicher (10 out of 13 patents)

10. Albert W Tam (10 out of 14 patents)

11. Patrice O Yarbough (8 out of 11 patents)

12. Kenneth G Hadlock (6 out of 12 patents)

13. Dong-Fang Shi (6 out of 8 patents)

14. Daniel W Bradley (6 out of 11 patents)

15. Lisa M Turin (6 out of 6 patents)

Core Competencies:

Nucleoside Derivatives

Viral Infections

Antiviral Compounds

DNA-Binding Molecules

Hepatitis C

Bone Mineral Density

Antifungal Activity

Antibacterial Agents

Gene Expression

Molecular Cloning

HTLV

Peptide Antigens

72 patents: Sort by Forward Citations

1. 7612034 - Treatment of subnormal bone mineral density (2009-11-03),

2. 7511145 - Bicyclic heteroaryl derivatives (2009-03-31),

3. 7432248 - Nucleoside derivatives for treating Hepatitis C virus infection (2008-10-07),

4. 7425547 - Nucleoside derivatives for treating hepatitis C virus infection (2008-09-16),

5. 7414031 - 5-nitro-nucleoside compounds for treating viral infections (2008-08-19),

6. 7405204 - Nucleoside compounds for treating viral infections (2008-07-29),

7. 7304085 - Nitrogen-containing heteroaryl derivatives (2007-12-04),

8. 7244713 - Nucleoside compounds for treating viral infections (2007-07-17),

9. 7202223 - Nucleoside compounds for treating viral infections (2007-04-10),

10. 7189506 - DNA binding compound-mediated molecular switch system (2007-03-13),

11. 7169918 - [object Object] (2007-01-30),

12. 7157434 - Nucleoside compounds for treating viral infections (2007-01-02),

13. 7151089 - Nucleoside compounds for treating viral infections (2006-12-19),

14. 7144868 - Nucleoside compounds for treating viral infections (2006-12-05),

15. 7141680 - Aromatic compounds possessing antifungal or antibacterial activity (2006-11-28),

Company Overview

Genelabs Technologies, Inc., based in Redwood City, CA, specializes in the development of nucleoside derivatives with applications in antiviral therapies. The company focuses on innovative solutions for viral infections, particularly targeting Hepatitis C, and explores the potential of its compounds in enhancing bone mineral density and exhibiting antifungal and antibacterial activity. Through its research, Genelabs aims to advance the understanding and treatment of various infectious diseases, contributing to the broader field of medicinal chemistry.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

72 Patents

#31 in Redwood City, CA

#1,204 in California

#5,106 in US

#10,392 in the World

Redwood City, CA, United States of America

Genelabs Technologies, Inc.

Forward Citations = 1,190

73 inventors:

Kirk E Fry (19 out of 39 patents)

Gregory R Reyes (18 out of 27 patents)

Christopher Don Roberts (17 out of 22 patents)

4. Jungsuh P Kim (12 out of 13 patents)

5. Cynthia A Edwards (12 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genelabs Technologies, Inc.. Retrieved from https://idiyas.com/company/genelabs-technologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…